EDIT

+ Watchlist + Portfolio

Editas Medicine, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.25
52-Week Range: $1.66 – $4.54
Market Cap: $451.53M
P/E (TTM): —
EPS (TTM): -0.59
Dividend Yield: —

Advanced Metrics

Price/Book: 4.29
PEG Ratio: —
Return on Equity: -118.82%
Return on Assets: -23.29%
Gross Margin: -80.75%
Operating Margin: -167.31%
Profit Margin: -157.32%
Current Ratio: 3.19
Debt/Equity: 0.15
Total Debt: $15.51M
Free Cash Flow: $-44.32M
Revenue Growth: 232.30%
Earnings Growth: —
Enterprise Value: $252.32M

EDIT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$19.71M	$78.12M	$32.31M	$40.52M
Research & Development	$174.96M	$177.65M	$199.25M	$89.95M
Selling, General & Admin	$70.70M	$69.65M	$71.99M	$49.90M
Operating Expenses	$245.66M	$247.30M	$271.23M	$139.86M
Operating Income	-$225.95M	-$169.18M	-$238.92M	-$99.34M
EBITDA	-$219.61M	-$163.12M	-$229.09M	-$148.61M
Pretax Income	-$220.43M	-$153.22M	-$237.09M	-$160.06M
Net Income	-$220.43M	-$153.22M	-$237.09M	-$160.06M
Diluted EPS	-3.21	-2.02	-2.88	-1.80
Diluted Shares	68.66M	75.97M	82.34M	88.75M

EDIT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$141.52M	$123.65M	$131.54M	$146.65M
Receivables	$5.14M	$10.19M	$16.27M	$15.18M
Current Assets	$356.75M	$340.83M	$289.31M	$163.90M
Total Assets	$514.32M	$499.15M	$341.59M	$186.53M
Current Liabilities	$60.11M	$63.22M	$77.22M	$46.25M
Total Debt	$43.95M	$36.54M	$35.03M	$18.10M
Total Liabilities	$153.64M	$150.06M	$207.31M	$159.25M
Retained Earnings	-$1.08B	-$1.23B	-$1.47B	-$1.63B
Shareholders' Equity	$360.68M	$349.10M	$134.27M	$27.29M
Working Capital	$296.64M	$277.61M	$212.09M	$117.65M

EDIT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$177.35M	-$132.18M	-$210.28M	-$165.24M
Capital Expenditure	-$4.12M	-$4.72M	-$8.83M	-$607.00K
Free Cash Flow	-$181.47M	-$136.90M	-$219.11M	-$165.85M
Depreciation & Amortisation	$6.34M	$6.06M	$5.81M	$5.28M
Stock-Based Compensation	$29.29M	$19.80M	$21.42M	$10.00M
Investing Cash Flow	$114.07M	-$3.73M	$162.15M	$138.67M
Financing Cash Flow	$1.28M	$118.04M	$56.03M	$40.47M
Net Change in Cash	-$62.00M	-$17.87M	$7.89M	$13.90M

EDIT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$4.66M	$3.58M	$7.54M	$24.74M	$2.83M
Research & Development	$26.59M	$16.18M	$19.77M	$27.40M	$17.60M
Selling, General & Admin	$13.38M	$12.86M	$12.32M	$11.35M	$10.23M
Operating Expenses	$39.97M	$29.04M	$32.09M	$38.76M	$27.83M
Operating Income	-$35.31M	-$25.46M	-$24.55M	-$14.02M	-$25.00M
EBITDA	-$71.95M	-$49.38M	-$22.00M	-$5.28M	-$23.43M
Pretax Income	-$76.09M	-$53.23M	-$25.12M	-$5.62M	-$24.98M
Net Income	-$76.09M	-$53.23M	-$25.12M	-$5.62M	-$24.98M
Diluted EPS	-0.92	-0.63	-0.28	-0.06	-0.26
Diluted Shares	83.06M	84.41M	90.09M	97.26M	97.88M

EDIT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$138.69M	$138.54M	$165.65M	$146.65M	$123.65M
Receivables	$510.00K	$588.00K	$8.13M	$15.18M	$2.59M
Current Assets	$224.84M	$182.80M	$176.89M	$163.90M	$128.07M
Total Assets	$263.65M	$210.58M	$201.75M	$186.53M	$149.34M
Current Liabilities	$73.11M	$65.94M	$61.77M	$46.25M	$39.78M
Total Debt	$31.13M	$21.14M	$19.65M	$18.10M	$17.30M
Total Liabilities	$201.23M	$191.39M	$188.30M	$159.25M	$144.93M
Retained Earnings	-$1.54B	-$1.60B	-$1.62B	-$1.63B	-$1.65B
Shareholders' Equity	$62.42M	$19.19M	$13.45M	$27.29M	$4.41M
Working Capital	$151.73M	$116.86M	$115.12M	$117.65M	$88.29M

EDIT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$47.80M	-$50.21M	-$30.84M	-$36.39M	-$23.06M
Capital Expenditure	-$114.00K	—	-$433.00K	-$60.00K	-$92.00K
Free Cash Flow	-$47.91M	-$50.21M	-$31.28M	-$36.45M	-$23.15M
Depreciation & Amortisation	$1.92M	$1.83M	$721.00K	$805.00K	$483.00K
Stock-Based Compensation	$2.98M	$2.66M	$2.23M	$2.13M	$2.10M
Investing Cash Flow	$56.39M	$42.65M	$39.57M	$58.00K	$64.00K
Financing Cash Flow	-$1.44M	$7.41M	$17.17M	$17.33M	$0.00
Net Change in Cash	$7.15M	-$150.00K	$25.90M	-$19.00M	-$23.00M

Market Snapshot

About

Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing CRISPR gene editing therapies for serious diseases. The company's pipeline includes experimental treatments for inherited retinal diseases, sickle cell disease, cancer, and other genetic disorders using its proprietary CRISPR/Cas9 and Cas12a platforms. Editas is advancing multiple clinical trials including EDIT-101 for Leber congenital amaurosis 10, a rare form of inherited blindness. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company is among the pioneers commercializing CRISPR gene editing technology for human therapeutics.